Kardigan
CA - South SFBiotechnology
Focus: Kardigan is a Series B cardiovascular-focused biotechnology company developing small-molecule therapies for heart disease, headquartered in South San Francisco. The company is advancing a pipeline of three clinical-stage programs targeting hypertension, cardiomyopathy, and aortic valve stenosis.
Profile data last refreshed 5h ago · AI intelligence enriched 1w ago
Funding Stage
SERIES B
Open Jobs
34-2 this month
Stable — net -2 jobs in 30d
13 added, 15 removed. Backfill posture.
Should You Work at Kardigan?
AI assessmentKardigan is a high-risk, high-reward growth-stage play suitable for professionals betting on late-stage clinical success and the near-term capital event of an IPO.
Why Work Here
- Active IPO filing (May 2026) signals capital influx and potential equity upside for early-stage employees
- Medical Affairs hiring surge (7 open roles) indicates commercial infrastructure build-out ahead of Phase 3 readouts
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Tonlamarsen
HypertensionClinical Trials (2)
NCT06864104A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)
Phase 2Help build intelligence for Kardigan
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.